AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to AppCellar's first quarter 2025 business update and conference call. My name is Jasmine and I will facilitate the audio portion of today's interactive broadcast. All lines will be muted during the presentation portion of the call with the opportunity for questions and answers at the end. If you would like to ask a question, press star one on your telephone keypad. If any assistance is needed during the call, please press star zero to speak with an operator. At this time, I would like to turn the call over to Trent Steinmart, Abcelera's Chief Legal and Compliance Officer. You may proceed. Thank you. Hello, everyone. Thank you for joining us for Abcelera's first quarter 2025 earnings call. I'm Trent Steinmart, Abcelera's Chief Legal and Compliance Officer. Dr. Carl Hansen, Abcelera's President and Chief Executive Officer, and Andrew Booth, Abcelera's Chief Financial Officer, are joining me on today's call. During this call, we anticipate making projections and forward-looking statements based on our current expectations and according to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to several factors outlined in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Abseller is not obligated to update any forward-looking statements, whether due to new information, future events, or otherwise. Our presentation today, including our earnings press release and SEC filings published earlier today, are available on our investor relations website. The information we provide about our pipeline is for the benefit of the investment community and is not intended to be promotional. As we transition to our prepared rema...